210 related articles for article (PubMed ID: 33804620)
1. Parallel G-quadruplex Structures Increase Cellular Uptake and Cytotoxicity of 5-Fluoro-2'-deoxyuridine Oligomers in 5-Fluorouracil Resistant Cells.
Clua A; Fàbrega C; García-Chica J; Grijalvo S; Eritja R
Molecules; 2021 Mar; 26(6):. PubMed ID: 33804620
[TBL] [Abstract][Full Text] [Related]
2. DNA-based nanoscaffolds as vehicles for 5-fluoro-2'-deoxyuridine oligomers in colorectal cancer therapy.
Jorge AF; Aviñó A; Pais AACC; Eritja R; Fàbrega C
Nanoscale; 2018 Apr; 10(15):7238-7249. PubMed ID: 29632908
[TBL] [Abstract][Full Text] [Related]
3. Loss of Uracil DNA Glycosylase Selectively Resensitizes p53-Mutant and -Deficient Cells to 5-FdU.
Yan Y; Qing Y; Pink JJ; Gerson SL
Mol Cancer Res; 2018 Feb; 16(2):212-221. PubMed ID: 29117941
[TBL] [Abstract][Full Text] [Related]
4. [Antisense oligonucleotides with antitumor activity].
Otvös L; Sági G
Magy Onkol; 2004; 48(3):221-7. PubMed ID: 15520872
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Human Uracil DNA Glycosylase Sensitizes a Large Fraction of Colorectal Cancer Cells to 5-Fluorodeoxyuridine and Raltitrexed but Not Fluorouracil.
Christenson ES; Gizzi A; Cui J; Egleston M; Seamon KJ; DePasquale M; Orris B; Park BH; Stivers JT
Mol Pharmacol; 2021 Jun; 99(6):412-425. PubMed ID: 33795350
[TBL] [Abstract][Full Text] [Related]
6. Novel anticancer polymeric conjugates of activated nucleoside analogues.
Senanayake TH; Warren G; Vinogradov SV
Bioconjug Chem; 2011 Oct; 22(10):1983-93. PubMed ID: 21863885
[TBL] [Abstract][Full Text] [Related]
7. Tuning G-Quadruplex Nanostructures with Lipids. Towards Designing Hybrid Scaffolds for Oligonucleotide Delivery.
Grijalvo S; Clua A; Eres M; Gargallo R; Eritja R
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33374392
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and anticancer activity of some 5-fluoro-2'-deoxyuridine phosphoramidates.
Lewandowska M; Ruszkowski P; Chojnacka K; Kleczewska N; Hoffmann M; Kacprzak K; Celewicz L
Bioorg Med Chem; 2016 May; 24(10):2330-41. PubMed ID: 27073055
[TBL] [Abstract][Full Text] [Related]
9. New 3'-O-aromatic acyl-5-fluoro-2'-deoxyuridine derivatives as potential anticancer agents.
Szymańska-Michalak A; Wawrzyniak D; Framski G; Kujda M; Zgoła P; Stawinski J; Barciszewski J; Boryski J; Kraszewski A
Eur J Med Chem; 2016 Jun; 115():41-52. PubMed ID: 26994842
[TBL] [Abstract][Full Text] [Related]
10. Increased cytotoxicity and decreased in vivo toxicity of FdUMP[10] relative to 5-FU.
Liu J; Skradis A; Kolar C; Kolath J; Anderson J; Lawson T; Talmadge J; Gmeiner WH
Nucleosides Nucleotides; 1999 Aug; 18(8):1789-802. PubMed ID: 10478484
[TBL] [Abstract][Full Text] [Related]
11. An aptamer intrinsically comprising 5-fluoro-2'-deoxyuridine for targeted chemotherapy.
Kruspe S; Hahn U
Angew Chem Int Ed Engl; 2014 Sep; 53(39):10541-4. PubMed ID: 25145319
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and anticancer activities of amphiphilic 5-fluoro-2'-deoxyuridylic acid prodrugs.
Ludwig PS; Schwendener RA; Schott H
Eur J Med Chem; 2005 May; 40(5):494-504. PubMed ID: 15893023
[TBL] [Abstract][Full Text] [Related]
13. [Potentiation of 5-fluorouracil efficacy. Molecular mechanisms playing a role in the cytotoxic action of 5-fluorouracil and 5-ethyl-2'-deoxyuridine (EUdR) combination].
Katona C; Timár F; Oláh J; Bocsi J; Budai B; Otvös L; Kralovánszky J
Magy Onkol; 2004; 48(3):243-51. PubMed ID: 15520875
[TBL] [Abstract][Full Text] [Related]
14. G-quadruplex oligonucleotide AS1411 as a cancer-targeting agent: Uses and mechanisms.
Bates PJ; Reyes-Reyes EM; Malik MT; Murphy EM; O'Toole MG; Trent JO
Biochim Biophys Acta Gen Subj; 2017 May; 1861(5 Pt B):1414-1428. PubMed ID: 28007579
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological evaluation of butanoate, retinoate, and bis(2,2,2-trichloroethyl)phosphate derivatives of 5-fluoro-2'-deoxyuridine and 2',5-difluoro-2'-deoxyuridine as potential dual action anticancer prodrugs.
Xia Z; Wiebe LI; Miller GG; Knaus EE
Arch Pharm (Weinheim); 1999 Aug; 332(8):286-94. PubMed ID: 10489539
[TBL] [Abstract][Full Text] [Related]
16. Cytostatic activity of a 5-fluoro-2'-deoxyuridine-alendronate conjugate against gastric adenocarcinoma and non-malignant intestinal and fibroblast cell lines.
Weinreich J; Schott TC; Königsrainer I; Küper M; Königsrainer A; Schott H
Anticancer Res; 2012 Oct; 32(10):4299-305. PubMed ID: 23060550
[TBL] [Abstract][Full Text] [Related]
17. Targeted drug delivery to chemoresistant cells: folic acid derivatization of FdUMP[10] enhances cytotoxicity toward 5-FU-resistant human colorectal tumor cells.
Liu J; Kolar C; Lawson TA; Gmeiner WH
J Org Chem; 2001 Aug; 66(17):5655-63. PubMed ID: 11511236
[TBL] [Abstract][Full Text] [Related]
18. Augmentation of 5-fluoro-2'-deoxyuridine cytotoxicity by 5-phenethyl-2'-deoxyuridine in human gastric cancer cells in culture.
Tokuzen R; Yamaguchi T; Saneyoshi M; Yoshida M; Maeda M
Anticancer Drugs; 1994 Aug; 5(4):419-23. PubMed ID: 7949245
[TBL] [Abstract][Full Text] [Related]
19. Engineered exosomes for targeted co-delivery of miR-21 inhibitor and chemotherapeutics to reverse drug resistance in colon cancer.
Liang G; Zhu Y; Ali DJ; Tian T; Xu H; Si K; Sun B; Chen B; Xiao Z
J Nanobiotechnology; 2020 Jan; 18(1):10. PubMed ID: 31918721
[TBL] [Abstract][Full Text] [Related]
20. AS1411 derivatives as carriers of G-quadruplex ligands for cervical cancer cells.
Figueiredo J; Lopes-Nunes J; Carvalho J; Antunes F; Ribeiro M; Campello MPC; Paulo A; Paiva A; Salgado GF; Queiroz JA; Mergny JL; Cruz C
Int J Pharm; 2019 Sep; 568():118511. PubMed ID: 31301466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
